Rafael Escandón

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 261 citations

Medicine, Cardiology, Pharmacology +11

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

Marcelo E. Bigal, Rafael Escandón, Michele Bronson et al. · Cephalalgia · 2013 · 94 citations

Medicine, Pharmacology, Pharmacotherapy +12

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

Barry Greenberg, Willis Chou, Khalil G. Saikali et al. · JACC Heart Failure · 2014 · 65 citations · Full text

Medicine, Cardiology, Pharmacology +17

Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP

Marcelo E. Bigal, Sarah Walter, Michele Bronson et al. · Cephalalgia · 2014 · 60 citations

Medicine, Cardiology, Pharmacology +15

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Henry Gómez, M. Philco, Patricia Pimentel et al. · Anti-Cancer Drugs · 2011 · 57 citations

Pharmacy, Pharmacokinetics, Pharmacology +17